The combination of ledipasvir + sofosbuvir was highly effective in a small study of people with HCV genotype 6.
Researchers recruited 25 participants with the following average profile:
After 12 weeks of ledipasvir + sofosbuvir, 96% (24 of 25 participants) achieved an SVR12.
At this time further information about the trial is not available. However, note that the study was small and the results, although very promising, require confirmation in a larger clinical trial.
Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infections. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract LB-11.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Sex and the HIV Reservoir: New Research Points to the Powerful Effect of Estrogen|
|First U.S. Failure of Truvada as PrEP Is Reported at IDWeek|
|Post-AIDS 2018 Updates on HIV Cure Research|
|On-Demand PrEP Is Great. Now, What About Women?|
|High Rates of Anal HPV Infection in Gay Men Using PrEP in IPERGAY: The Role of Vaccination|